AIM: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). METHODS: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. RESULTS: The mean size of HCC tumors was 2.4 +/- 1.1 cm, and the mean number of TACE procedures performed was 2.5 +/- 2.1. The mean overall survival time and 1-, 5-, and 10-year surviv...
BACKGROUND & AIMS: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed in s...
Purpose: Patients with hepatocellular carcinoma (HCC) of intermediate stage (BCLC-B according to the...
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer...
Introduction: Trans-arterial chemoembolization (TACE) is a mainstay therapeutic option indicated in ...
Aim: To assess clinical outcome of transarterial chemoembolization (TACE) in a series of patients wi...
Aim: To assess clinical outcome of transarterial chemoembolization (TACE) in a series of patients wi...
Aims: To evaluate the outcome following transarterial chemoembolization (TACE) and to identify the p...
OBJECTIVE was to evaluate the results of transcatheter arterial chemoembolization (TACE) in the trea...
AbstractBackgroundHepatocelluar carcinoma (HCC) is a major health problem in Egypt as well as in man...
Transarterial chemoembolization (TACE) could achieve a better survival benefit than conservative tre...
BACKGROUND: Tumor response and survival varies in patients treated with transarterial chemoembolizat...
Introduction: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. L...
Background: Trans-arterial chemoembolization (TACE) is associated with better survival in BCLC-stage...
BACKGROUND: Tumor response and survival varies in patients treated with transarterial chemoembolizat...
Background & Aims: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed ...
BACKGROUND & AIMS: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed in s...
Purpose: Patients with hepatocellular carcinoma (HCC) of intermediate stage (BCLC-B according to the...
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer...
Introduction: Trans-arterial chemoembolization (TACE) is a mainstay therapeutic option indicated in ...
Aim: To assess clinical outcome of transarterial chemoembolization (TACE) in a series of patients wi...
Aim: To assess clinical outcome of transarterial chemoembolization (TACE) in a series of patients wi...
Aims: To evaluate the outcome following transarterial chemoembolization (TACE) and to identify the p...
OBJECTIVE was to evaluate the results of transcatheter arterial chemoembolization (TACE) in the trea...
AbstractBackgroundHepatocelluar carcinoma (HCC) is a major health problem in Egypt as well as in man...
Transarterial chemoembolization (TACE) could achieve a better survival benefit than conservative tre...
BACKGROUND: Tumor response and survival varies in patients treated with transarterial chemoembolizat...
Introduction: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. L...
Background: Trans-arterial chemoembolization (TACE) is associated with better survival in BCLC-stage...
BACKGROUND: Tumor response and survival varies in patients treated with transarterial chemoembolizat...
Background & Aims: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed ...
BACKGROUND & AIMS: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed in s...
Purpose: Patients with hepatocellular carcinoma (HCC) of intermediate stage (BCLC-B according to the...
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer...